Table 2 Characteristics of ovarian cancer patients, N = 5,213.
From: The impact of comorbidity and stage on ovarian cancer mortality: A nationwide Danish cohort study
| Â | Charlson Comorbidity score | ||
|---|---|---|---|
|  | Comorbidity 0 | Comorbidity 1–2 | Comorbidity 3+ |
Number | 3,727 (72%) | 1,116 (21%) | 370 (7%) |
Median age, years | 62 | 70 | 71 |
(25% – 75% percentile) | (52–72) | (59–77) | (62–78) |
Age groups | Â | Â | Â |
   < 50 years | 726 (19%) | 96 (9%) | 21 (6%) |
   50–69 years | 1,897 (51%) | 474 (42%) | 153 (41%) |
   70–89 years | 1,079 (29%) | 521 (47%) | 188 (51%) |
   90+ years | 25 (< 1%) | 25 (2%) | 8 (2%) |
Year of diagnosis | Â | Â | Â |
   1995–1997 | 1,278 (74%) | 336 (19%) | 119 (7%) |
   1998–2000 | 1,300 (71%) | 406 (22%) | 119 (7%) |
   2001–2003 | 1,149 (69%) | 374 (23%) | 132 (8%) |
Extent of cancer | Â | Â | Â |
   Localized/FIGO I | 774 (21%) | 184 (16%) | 37 (10%) |
   Regional/FIGO II and III | 1,757 (47%) | 492 (44%) | 157 (42%) |
   Distant metastases/FIGO IV | 1,002 (27%) | 338 (30%) | 140 (38%) |
   Unspecified/missing | 194 (5%) | 102 (9%) | 36 (10%) |
Histological type | Â | Â | Â |
   Epithelial | 3,422 (92%) | 985 (88%) | 322 (87%) |
   Non-epithelial | 305 (8%) | 131 (12%) | 48 (13%) |
Treatment | Â | Â | Â |
   Surgery/Chemotherapy | 1,753 (47%) | 378 (34%) | 101 (27%) |
   Surgery | 1,416 (38%) | 442 (40%) | 132 (36%) |
   Chemotherapy | 230 (6%) | 94 (8%) | 32 (9%) |
   Other* | 12 (< 1%) | 9 (< 1%) | 6 (2%) |
   No/Symptomatic | 285 (8%) | 178 (16%) | 94 (25%) |
   Missing | 31 (< 1%) | 15 (1%) | 5 (1%) |